Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

NEW HAVEN, Conn., March 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VIOND) today announced financial results for the fourth quarter and year-end of 2007.

The Company reported a net loss of $34.0 million, or $5.05 per share, for the year ended December 31, 2007, compared with a net loss of $25.3 million, or $3.83 per share, for 2006. Weighted-average common shares outstanding for the years ended December 31, 2007 and December 31, 2006 were 6.7 million and 6.6 million, respectively. The net loss increased in 2007 by $8.7 million over the previous year, primarily as a result of non-cash expenses including: (i) $5.1 million of interest expense related to Vion's convertible senior notes and (ii) $2.5 million of higher stock-based compensation expense. In addition, costs associated with clinical, regulatory and pre-commercialization activities for the Company's lead product candidate, Cloretazine(R) (VNP40101M) increased year-over-year.

The Company reported ending the year with $61.1 million in cash and cash equivalents.

Alan Kessman, Chief Executive Officer, commented, "Based on our current operating plan, we are funded through the third quarter of 2009. We continue to make progress on preparing a New Drug Application for our lead anticancer agent Cloretazine(R) (VNP40101M) for filing with the U.S. Food and Drug Administration in 2008."

A net loss of $8.2 million, or $1.18 per share, was reported for the fourth quarter of 2007, compared with a net loss of $6.1 million, or $0.92 per share, for the same period in 2006. Weighted-average common shares outstanding for the three months ended December 31, 2007 and 2006 were 6.9 million and 6.6 million, respectively.

On February 20, 2008, the Co
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Costa Mesa, CA (PRWEB) , ... July 01, 2015 , ... ... and traumatic brain injury (TBI) using single photon emission computed tomography (SPECT) ... Columbia. The study, which examined over 20,000 brain scans and is believed to ...
(Date:7/1/2015)... and BANGALORE, India , July 1, ... company that uses next generation sequencing technology to empower ... A. Storrer as chief executive officer. In his ... be responsible for all strategy, business expansion and worldwide ... has served as Strand,s chairman and CEO since its ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest will ... barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 ... US$15,000 and a period of expert mentorship from a senior industry figure drawn from ...
(Date:7/1/2015)... July 1, 2015  UCB, a multinational biopharmaceutical ... global leader in designing, transforming, and running intelligent ... in recognition of their close collaboration in driving ... global business services (GBS) finance organization. ... clients that work together effectively to embrace the ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... MONROVIA, Calif., March 4 STAAR Surgical Company,(Nasdaq: ... financial results for the,fourth quarter and full year ended ... the market close. The Company will host a ... 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss,the ...
... Overcoming a critical conductivity challenge to clean ... titanium nanostructure that provides an expanded surface area ... of electrons. , The challenge has vexed researchers ... yet thin enough to collect and transport electrons ...
... in prominence as viable vehicle and jet fuel feedstockGREAT ... and researchers of camelina have formed the first trade ... America. The North American Camelina Trade Association (NACTA) ... of new markets for camelina - a relatively new ...
Cached Biology Technology:STAAR Surgical Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call 2Nanostructure boosts efficiency in energy transport 2New Trade Association Formed for North America Camelina Industry 2New Trade Association Formed for North America Camelina Industry 3
(Date:6/17/2015)... PALM BEACH GARDENS, Fla. , June 17, ... identity management solutions, today announced that its U.are.U ... by Togo,s Eateries, Inc., ... based fast casual sandwich chain, to increase security, ... (POS). The Crossmatch fingerprint readers enable instant, non-repudiable identity ...
(Date:6/15/2015)... June 16, 2015 According to ... by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, ... 2020" published by MarketsandMarkets, The Natural Language Processing Market ... CAGR of 18.4% for the forecast period 2015-2020. ... 46 F igures spread   through 155 P ...
(Date:6/10/2015)... 2015 According to a ... Technology (Ultrasound, TOF, Structured Light, Stereo Vision), Type(Image, ... and by Geography - Trends & Forecast to ... is expected to reach $3,319.71 Million by 2020, ... and 2020. Browse 71 market data ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 53D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4
... team using a novel genetic cloning and sequencing technique has ... Midwest therapy pool, pointing to the need for closer scrutiny ... by Washington University in St. Louis and involving the University ... new study assessed the microbe population in a warm hospital ...
... scientists have been studying how external information gets transmitted ... them that trigger particular responses. But cell signaling networks ... slow, arduous process. , Now, a research team from ... for charting cellular signaling networks quickly and accurately. Their ...
... Drug Administration (FDA) has granted approval to Mylan Technologies, ... Duragesic Patch (Fentanyl Transdermal System) used to treat patients ... with alternative analgesics. When applied to the skin, this ... is slowly absorbed into the body through the skin ...
Cached Biology News:New lab technique identifies high levels of pathogens in therapy pool 2New lab technique identifies high levels of pathogens in therapy pool 3Computational Method Speeds Mapping of Cell Signaling Networks 2Computational Method Speeds Mapping of Cell Signaling Networks 3
... developed for use with immunohistochemical (IHC) ... background staining due to endogenous peroxidase. ... with hydrogen peroxide. This reagent ... additional novel components to further quench ...
Phospho-Btk (Tyr223) Antibody...
Rad51B...
p27 rabbit polyclonal antibody...
Biology Products: